Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Rt.

Györgyi Vereczkeyné Donáth

Kálmán Nagy

Gyula Simig

Gyuláné Körtvélyessy

Tibor Mezei

József Reiter

László Pongó

József Barkóczy

Ferenc Lorant Bartha

Márta Porcs-Makkay

Balázs Volk

Péter Trinka

Péter Kótay Nagy

Gyula Lukács

Zsuzsanna Szent-Királlyi

Enikó Molnár

János Szulágyi

Tamás Gregor

Gábor Berecz

György Clementis

Zoltán Katona

Norbert Mesterházy

Éva Pécsi

László Koncz

Péter Slégel

Béla Farkas

Valéria Hofmanné Fekete

Zsuzsanna Évinger

György Krasznay

Gábor Nemeth

Györgyi Kovanyine Lax

György Krasznai

Enikõ Molnár

József Barkoczy

Péter Kotay Nagy

Gyuláné Körtvelyessy

According to the present invention, 2-chloroethoxy-acetic acid-N,N-dimethylamide of the Formula (I) is prepared by reacting 2-hydroxyethoxy-acetic acid-N,N-dimethylamide of the Formula (II) in a solvent optionally in the presence of a catalyst with thionyl chloride and removing the solvent by distillation. 

[object Object]

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b] [1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound. 

Process for the preparation of olanzapine

The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I) 

Process for the preparation of amorphous form of a platelet aggregation inhibitor drug

The invention relates to a process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula (I), and pharmaceutically acceptable acid addition salts thereof by subjecting the oxime of the Formula (II), to ring-closure in the presence of an alkali hydroxide, alkali carbonate or alkali-Calkoxide in an inert organic solvent, converting the base of the Formula I thus obtained into an acid addition salt or setting free the base of the Formula I from an acid addition salt thereof which comprises reacting a halogen derivative of the general Formula (XIV), (wherein Hal is halogen) with piperidine oxime derivative of the Formula (V), or an acid addition salt thereof in the presence of a base, and using by the ring-closure of the oxime of the Formula II formed a C-alkanol as inert solvent. The process of the present invention enables the economical preparation of a product having a purity suitable for pharmaceutical purposes.

Process for the preparation of 3-{2-'4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyllethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido&#x2032;1,2-methyl-4h-pyrido&#x2032;,2-a!pyrimidin-4-one

Growing community of inventors

Budapest, Hungary

Györgyi Vereczkeyné Donáth